Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas.

Espensen CA, Appelt AL, Fog LS, Gothelf AB, Thariat J, Kiilgaard JF.

Cancers (Basel). 2019 Aug 6;11(8). pii: E1124. doi: 10.3390/cancers11081124.

2.

Method for Automatic Selection of Parameters in Normal Tissue Complication Probability Modeling.

Christophides D, Appelt AL, Gusnanto A, Lilley J, Sebag-Montefiore D.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):704-712. doi: 10.1016/j.ijrobp.2018.02.152. Epub 2018 Mar 6.

3.

Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review.

Teo MTW, McParland L, Appelt AL, Sebag-Montefiore D.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):146-158. doi: 10.1016/j.ijrobp.2017.09.042. Epub 2017 Sep 29. Review.

4.

Metal artefact reduction for accurate tumour delineation in radiotherapy.

Kovacs DG, Rechner LA, Appelt AL, Berthelsen AK, Costa JC, Friborg J, Persson GF, Bangsgaard JP, Specht L, Aznar MC.

Radiother Oncol. 2018 Mar;126(3):479-486. doi: 10.1016/j.radonc.2017.09.029. Epub 2017 Oct 16.

5.

Feasibility of preference-driven radiotherapy dose treatment planning to support shared decision making in anal cancer.

Rønde HS, Wee L, Pløen J, Appelt AL.

Acta Oncol. 2017 Oct;56(10):1277-1285. doi: 10.1080/0284186X.2017.1315174. Epub 2017 Apr 27.

6.

Technological advances in radiotherapy of rectal cancer: opportunities and challenges.

Appelt AL, Sebag-Montefiore D.

Curr Opin Oncol. 2016 Jul;28(4):353-8. doi: 10.1097/CCO.0000000000000306. Review.

7.

High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.

Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JC, Lindebjerg J, Rafaelsen SR, Jakobsen A.

Lancet Oncol. 2015 Aug;16(8):919-27. doi: 10.1016/S1470-2045(15)00120-5. Epub 2015 Jul 5.

8.

Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost.

Appelt AL, Vogelius IR, Pløen J, Rafaelsen SR, Lindebjerg J, Havelund BM, Bentzen SM, Jakobsen A.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):110-8. doi: 10.1016/j.ijrobp.2014.05.023. Epub 2014 Jul 8.

9.

Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer.

Appelt AL, Bentzen SM, Jakobsen A, Vogelius IR.

Acta Oncol. 2015 Feb;54(2):179-86. doi: 10.3109/0284186X.2014.923933. Epub 2014 Jun 30.

10.

Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.

Spindler KL, Appelt AL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A.

Int J Cancer. 2014 Dec 15;135(12):2984-91. doi: 10.1002/ijc.28946. Epub 2014 Jun 17.

11.

Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors.

Appelt AL, Vogelius IR, Farr KP, Khalil AA, Bentzen SM.

Acta Oncol. 2014 May;53(5):605-12. doi: 10.3109/0284186X.2013.820341. Epub 2013 Aug 19.

PMID:
23957623
12.

Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients.

Nissen HD, Appelt AL.

Radiother Oncol. 2013 Jan;106(1):28-32. doi: 10.1016/j.radonc.2012.10.016. Epub 2012 Nov 28.

PMID:
23199652
13.

Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.

Appelt AL, Pløen J, Vogelius IR, Bentzen SM, Jakobsen A.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):74-80. doi: 10.1016/j.ijrobp.2012.05.017. Epub 2012 Jul 3.

14.

A method to adjust radiation dose-response relationships for clinical risk factors.

Appelt AL, Vogelius IR.

Radiother Oncol. 2012 Mar;102(3):352-4. doi: 10.1016/j.radonc.2011.08.031. Epub 2011 Oct 6.

PMID:
21981874

Supplemental Content

Loading ...
Support Center